← Eichor
Condition: Xla Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Xla

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Long-term Extension Study of PCI-32765 (Ibrutinib)
Phase 3 · 175 location(s) · Janssen Research & Development, LLC · NCT01804686A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib
Phase 3 · 91 location(s) · BeOne Medicines · NCT07277231A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Le
Phase 2 · 11 location(s) · Curis, Inc. · NCT07271667A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Phase 1 · 9 location(s) · Accutar Biotechnology Inc · NCT05780034Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemi
Phase N/A · 8 location(s) · BeiGene · NCT05640102Analysis of the Role of IgE Proteoforms in Health and Disease
Phase N/A · 1 location(s) · KU Leuven · NCT07328178Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After Previous Treatment With Zanubrutinib
Phase 2 · 3 location(s) · Peter MacCallum Cancer Centre, Australia · NCT06812715Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Rel
Phase 2 · 21 location(s) · Fondazione Italiana Linfomi - ETS · NCT05249959Innovative Biomarkers of Cardiovascular Complications Associated With Second-generation Bruton Tyrosine Kinase Inhibitor
Phase N/A · 1 location(s) · Centre Hospitalier Universitaire Dijon · NCT07174141A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Phase 1/Phase 2 · 127 location(s) · BeOne Medicines · NCT05006716A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymp
Phase 2 · 4 location(s) · VA Office of Research and Development · NCT06520098IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma
Phase 3 · 20 location(s) · Ono Pharmaceutical Co., Ltd. · NCT07104032A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lympho
Phase 3 · 124 location(s) · BeOne Medicines · NCT06846671Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors
NA · 1 location(s) · Northwell Health · NCT05643235Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Deg
Phase 1/Phase 2 · 29 location(s) · BeiGene · NCT05294731A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relap
Phase 1/Phase 2 · 50 location(s) · BeOne Medicines · NCT06634589A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Ch
Phase 3 · 197 location(s) · BeOne Medicines · NCT06973187A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocy
Phase 2 · 131 location(s) · Loxo Oncology, Inc. · NCT06588478LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
Phase 1 · 1 location(s) · Medical College of Wisconsin · NCT05990465Immune Regulation in Patients With Common Variable Immunodeficiency and Related Inborn Errors of Immunity (IEI)
Phase N/A · 1 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT00001244A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymp
Phase 2 · 32 location(s) · Nurix Therapeutics, Inc. · NCT07221500Determinants of the Response to BTK Degraders (BTKd) in Chronic Lymphocytic Leukemia
Phase N/A · 14 location(s) · Nantes University Hospital · NCT07099443A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Phase 1 · 16 location(s) · Nurix Therapeutics, Inc. · NCT04830137Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia
Phase 2 · 4 location(s) · Inhye Ahn · NCT06333262Current Status of BTKi Treatment for CLL/SLL in China
Phase N/A · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT06508684Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies U
Phase N/A · 1 location(s) · Mayo Clinic · NCT06151730Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
Phase 1 · 1 location(s) · Theodore S. Johnson · NCT05106296A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Phase 1 · 62 location(s) · Nurix Therapeutics, Inc. · NCT05131022CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary
Phase 1/Phase 2 · 45 location(s) · Curis, Inc. · NCT03328078
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.